K Pajtler
K Pajtler
Unknown affiliation
Verified email at dkfz.de
Title
Cited by
Cited by
Year
DNA methylation-based classification of central nervous system tumours
D Capper, DTW Jones, M Sill, V Hovestadt, D Schrimpf, D Sturm, ...
Nature 555 (7697), 469-474, 2018
6432018
Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups
KW Pajtler, H Witt, M Sill, DTW Jones, V Hovestadt, F Kratochwil, K Wani, ...
Cancer cell 27 (5), 728-743, 2015
5562015
New brain tumor entities emerge from molecular classification of CNS-PNETs
D Sturm, BA Orr, UH Toprak, V Hovestadt, DTW Jones, D Capper, M Sill, ...
Cell 164 (5), 1060-1072, 2016
4182016
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy
JH Schulte, S Lim, A Schramm, N Friedrichs, J Koster, R Versteeg, I Ora, ...
Cancer research 69 (5), 2065-2071, 2009
4162009
The landscape of genomic alterations across childhood cancers
SN Gröbner, BC Worst, J Weischenfeldt, I Buchhalter, K Kleinheinz, ...
Nature 555 (7696), 321-327, 2018
4002018
Cancer screening recommendations for individuals with Li-Fraumeni syndrome
CP Kratz, MI Achatz, L Brugieres, T Frebourg, JE Garber, MLC Greer, ...
Clinical Cancer Research 23 (11), e38-e45, 2017
1882017
The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants
KW Pajtler, SC Mack, V Ramaswamy, CA Smith, H Witt, A Smith, ...
Acta neuropathologica 133 (1), 5-12, 2017
1582017
Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation
A Sprüssel, JH Schulte, S Weber, M Necke, K Händschke, T Thor, ...
Leukemia 26 (9), 2039-2051, 2012
1372012
Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort
SM Waszak, PA Northcott, I Buchhalter, GW Robinson, C Sutter, ...
The Lancet Oncology 19 (6), 785-798, 2018
1212018
Accurate prediction of neuroblastoma outcome based on miRNA expression profiles
JH Schulte, B Schowe, P Mestdagh, L Kaderali, P Kalaghatgi, S Schlierf, ...
International journal of cancer 127 (10), 2374-2385, 2010
1032010
High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma
JH Schulte, HS Bachmann, B Brockmeyer, K DePreter, A Oberthür, ...
Clinical Cancer Research 17 (15), 5082-5092, 2011
1012011
Therapeutic impact of cytoreductive surgery and irradiation of posterior fossa ependymoma in the molecular era: a retrospective multicohort analysis
V Ramaswamy, T Hielscher, SC Mack, A Lassaletta, T Lin, KW Pajtler, ...
Journal of Clinical Oncology 34 (21), 2468, 2016
1002016
Childhood cancer predisposition syndromes—a concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology
T Ripperger, SS Bielack, A Borkhardt, IB Brecht, B Burkhardt, ...
American journal of medical genetics Part A 173 (4), 1017-1037, 2017
972017
Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling
SC Mack, KW Pajtler, L Chavez, K Okonechnikov, KC Bertrand, X Wang, ...
Nature 553 (7686), 101-105, 2018
902018
Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas
KW Pajtler, J Wen, M Sill, T Lin, W Orisme, B Tang, JM Hübner, ...
Acta neuropathologica 136 (2), 211-226, 2018
702018
Recommendations for cancer surveillance in individuals with RASopathies and other rare genetic conditions with increased cancer risk
A Villani, MLC Greer, JM Kalish, A Nakagawara, KL Nathanson, ...
Clinical Cancer Research 23 (12), e83-e90, 2017
582017
Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas
A Künkele, K De Preter, L Heukamp, T Thor, KW Pajtler, W Hartmann, ...
Neuro-oncology 14 (7), 859-869, 2012
542012
EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma
JM Hübner, T Müller, DN Papageorgiou, M Mauermann, J Krijgsveld, ...
Neuro-oncology 21 (7), 878-889, 2019
402019
Molecular mechanisms and therapeutic targets in pediatric brain tumors
KW Liu, KW Pajtler, BC Worst, SM Pfister, RJ Wechsler-Reya
Science signaling 10 (470), 2017
372017
Telomere dysfunction and chromothripsis
A Ernst, DTW Jones, KK Maass, A Rode, KI Deeg, BMC Jebaraj, ...
International journal of cancer 138 (12), 2905-2914, 2016
362016
The system can't perform the operation now. Try again later.
Articles 1–20